Company Filing History:
2 out of 31 
1 out of 336 
Years Active: 2020
Title: Innovations and Contributions of Inventor Xavier Jacq
Introduction
Xavier Jacq is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of two patents to his name, Jacq's work focuses on advancing methodologies in the medical and biological sciences.
Latest Patents
Jacq's latest patents include "Methods of screening and treatment with USP4 inhibitors." This application relates to materials and methods for exploiting synthetic lethality and/or chemo-sensitisation in DNA damage response (DDR) pathways. In particular, it discusses the ubiquitin hydrolase protein Ubiquitin Specific Protease 4 (USP4) and its association with DDR pathways. The patent further describes the use of USP4 inhibitors in the treatment of cancer, specifically targeting tumours that are defective in double-strand break repair (DSBR) or resistant to platinum-based chemotherapy. Additionally, it outlines methodologies for measuring isopeptidase activity in biological samples in a high throughput manner. This invention focuses on the development of high throughput assays to monitor target engagement of isopeptidases, such as deubiquitylating enzymes, using small molecule inhibitors.
Career Highlights
Throughout his career, Jacq has worked with several prominent companies, including Mission Therapeutics Limited and Cambridge Enterprise Limited. His experience in these organizations has allowed him to further his research and development efforts in the field of cancer therapeutics.
Collaborations
Jacq has collaborated with notable colleagues, including Helen Robinson and Yaara Ofir-Rosenfeld. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Xavier Jacq's innovative work in the field of cancer treatment through his patents demonstrates his commitment to advancing medical science. His contributions are significant and continue to impact the landscape of cancer therapeutics.